Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Blood (2024) 143 (16): 1565–1575.

https://doi.org/10.1182/blood.2023022432

Published: 2024

Journal Articles

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Blood (2023) 142 (26): 2327–2331.

https://doi.org/10.1182/blood.2023021274

Published: 2023

Includes: Supplemental data

Journal Articles

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Ian W. Flinn, Susan O’Brien, Brad Kahl, Manish Patel, Yasuhiro Oki, Francine F. Foss, Pierluigi Porcu, Jeffrey Jones, Jan A. Burger, Nitin Jain, Virginia M. Kelly, Kerstin Allen, Mark Douglas, Jennifer Sweeney, Patrick Kelly, Steven Horwitz

Blood (2018) 131 (8): 877–887.

https://doi.org/10.1182/blood-2017-05-786566

Published: 2018

Includes: Supplemental data

Journal Articles

a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL

Ian Flinn, Yasuhiro Oki, MD, Manish Patel, Steven M. Horwitz, MD, Francine M. Foss, MD, Jennifer Sweeney, Kerstin Allen, MA, Mark Douglas, MS, Lori Steelman, Joi Dunbar, PharmD, Howard M. Stern, MD PhD, Patrick Kelly, MD, Brad Kahl, MD

Blood (2014) 124 (21): 802.

https://doi.org/10.1182/blood.V124.21.802.802

Published: 2014

Journal Articles

MYC Associated and Double Protein Lymphoma: Subset Analysis of SWOG S9704

Soham D. Puvvada, MD, Patrick J Stiff, MD, Michael Leblanc, PhD, James R. Cook, MD PhD, Brad Kahl, MD, Hongli Li, M.S., Lisa M. Rimsza, MD, Jonathan W. Friedberg, MD, Sonali M. Smith, MD

Blood (2014) 124 (21): 1710.

https://doi.org/10.1182/blood.V124.21.1710.1710

Published: 2014

Journal Articles

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

Kieron Dunleavy, MD, Michelle Fanale, MD, Ann LaCasce, MD, Ariela Noy, Paolo Caimi, MD, Samir Parekh, MD, John W Hayslip, MD, Deepa Jagadeesh, MD MPH, Raymond S Lord, Mary J Lechowicz, MD, Rakesh Gaur, MD, Andrea Lucas, RN, Louis M Staudt, MD PhD, Seth M. Steinberg, PhD, Brad Kahl, MD, Jonathan W. Friedberg, MD, Richard F Little, MPH, MD, Nancy L Bartlett, MD, Wyndham H Wilson, MD PhD

Blood (2014) 124 (21): 395.

https://doi.org/10.1182/blood.V124.21.395.395

Published: 2014

Journal Articles

Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab

Steven P. Treon, Jacob D. Soumerai, Zachary R. Hunter, Christopher J. Patterson, Leukothea Ioakimidis, Brad Kahl, Michael Boxer

Blood (2011) 118 (2): 276–281.

https://doi.org/10.1182/blood-2011-02-338558

Published: 2011

Journal Articles

Identification of Potential Prognostic Biomarkers in Mantle Cell Lymphoma by Array-Based Quantitative Nuclease Protection Assay

David T Yang, MD, Gene R Shaw, MD, PhD, Kreg M Grindle, Songwon Seo, Catherine Leith, MBBChir, Ken H Young, Brad Kahl, MD

Blood (2010) 116 (21): 2007.

https://doi.org/10.1182/blood.V116.21.2007.2007

Published: 2010

Journal Articles

Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies

Brad Kahl, MD, Andrew W Roberts, MBBS, PhD, John F Seymour, MD, Ranjana H. Advani, MD, Daniel Oscar Persky, MD, Jianning Yang, PhD, Yue Cui, PhD, Todd Busman, MS, Andrew Krivoshik, MD, Sari Enschede, MD, Rod Humerickhouse, MD

Blood (2010) 116 (21): 3943.

https://doi.org/10.1182/blood.V116.21.3943.3943

Published: 2010

Journal Articles

A Randomized Phase III Trial of ABVD Vs. Stanford V +/− Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496)

Leo I Gordon, MD, FACP, Fanxing Hong, PhD, Richard I Fisher, MD, Nancy L. Bartlett, MD, Joseph M. Connors, MD, Randy D. Gascoyne, MD, Henry Wagner, MD, Patrick J Stiff, MD, Bruce D. Cheson, MD, Mary Gospodarowicz, MD, FRCPC, Ranjana Advani, MD, Brad Kahl, MD, Jonathan W. Friedberg, MD, Kristie A. Blum, MD, Thomas M. Habermann, MD, Joseph Tuscano, Richard Hoppe, MD, Sandra J. Horning, MD

Blood (2010) 116 (21): 415.

https://doi.org/10.1182/blood.V116.21.415.415

Published: 2010

Journal Articles

A Phase 2, Double-Blind, Placebo-Controlled Trial of Rituximab + Galiximab Vs Rituximab + Placebo In Advanced Follicular Non-Hodgkin's Lymphoma (NHL)

Isabelle Bence-Bruckler, MD, FRCPC, David Macdonald, MD, FRCPC, Patrick J Stiff, MD, Byron McKinney, MS, Katherine L. Ruffner, MD, Lynn Wilson, Margaret Whiteley, BSc, Brad Kahl, MD

Blood (2010) 116 (21): 428.

https://doi.org/10.1182/blood.V116.21.428.428

Published: 2010

Journal Articles

R-CHOP Versus (vs) CHOP Followed by Maintenance Rituximab (MR) Vs Observation In Older Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Long-Term Follow-up of Intergroup E4494/C9793

Vicki A. Morrison, MD, Fangxin Hong, PhD, Thomas M. Habermann, MD, Richard I. Fisher, MD, Bruce D. Cheson, MD, Brad Kahl, MD, Sandra J. Horning, MD, Bruce A. Peterson, MD

Blood (2010) 116 (21): 589.

https://doi.org/10.1182/blood.V116.21.589.589

Published: 2010

Journal Articles

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Brad Kahl, MD, John C. Byrd, MD, Ian W. Flinn, MD, PhD, Nina Wagner-Johnston, MD, Stephen Spurgeon, MD, Don M Benson, Jr, MD, Richard R. Furman, MD, Jennifer R Brown, MD, PhD, Steven Coutre, MD, Brian Lannutti, PhD, Neil A. Giese, Ph.D., Roger G Ulrich, Ph.D., Heather K Webb, Ph.D., Sissy Peterman, Leanne Holes, Albert S Yu, MD

Blood (2010) 116 (21): 1777.

https://doi.org/10.1182/blood.V116.21.1777.1777

Published: 2010

Journal Articles

Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496

Ranjana Advani, MD, Fangxin Hong, PhD, Richard I Fisher, MD, Nancy L. Bartlett, MD, Sue Robinson, MD, Randy D. Gascoyne, MD, Henry Wagner, MD, Patrick J Stiff, MD, Bruce D. Cheson, MD, Douglas A. Stewart, MD, FRCP, Leo I Gordon, MD, FACP, Brad Kahl, MD, Jonathan W. Friedberg, MD, Kristie A. Blum, MD, Thomas M. Habermann, MD, Joseph Tuscano, MD, Richard Hoppe, MD, Sandra J. Horning, MD

Blood (2010) 116 (21): 416.

https://doi.org/10.1182/blood.V116.21.416.416

Published: 2010

Journal Articles

A Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell Lymphoma.

Ranjana Advani, MD, Sven De Vos, MD, PhD, Stephen M. Ansell, MD, Brad Kahl, MD, Bruce D. Cheson, MD, Nancy L. Bartlett, MD, Richard R. Furman, MD, Jane N. Winter, MD, Henry Kaplan, MD, David Dornan, PhD, Nancy Whiting, PharmD, BCOP, Jonathan Drachman, MD, Andres Forero-Torres, MD

Blood (2008) 112 (11): 1000.

https://doi.org/10.1182/blood.V112.11.1000.1000

Published: 2008

Journal Articles

Predictors of Clinical Outcome to Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath for Relapsed/Refractory CLL – A Study of the Eastern Cooperative Oncology Group, E2903.

Neil E. Kay, MD, Haesook T Kim, PhD., Sanford Kempin, MD, Charla Secreto, Traci Knox, Renee Tschumper, Diane F Jelinek, Stephanie Smoley, Daniel VanDyke, Joel Saltzman, MD, Steven T. Rosen, MD, Brad Kahl, MD, Martin S. Tallman, MD

Blood (2008) 112 (11): 1057.

https://doi.org/10.1182/blood.V112.11.1057.1057

Published: 2008

Journal Articles

VcR-CVAD Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A Phase II Study from the Wisconsin Oncology Network

Brad Kahl, Julie Chang, Jens Eickhoff, Leslie Gilbert, Eric Rogers, Jae Werndli, Michael Huie, Thomas McFarland, Michael Volk, Jules H. Blank, Natalie Callander, Walter Longo, Christopher Peterson

Blood (2008) 112 (11): 265.

https://doi.org/10.1182/blood.V112.11.265.265

Published: 2008

Journal Articles

Phase II Study of R-CHOP Followed by 90 Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499.

Mitchell R. Smith, MD, PhD, Lijun Zhang, Leo I. Gordon, MD, James Foran, MD, Brad Kahl, MD, Randy D. Gascoyne, MD, Ranjana Advani, MD, Elisabeth Paietta, MD, Edie Weller, PhD, Sandra J. Horning, MD

Blood (2007) 110 (11): 389.

https://doi.org/10.1182/blood.V110.11.389.389

Published: 2007

Journal Articles

Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma.

Brad Kahl, MD, Nancy L. Bartlett, MD, John P. Leonard, MD, Kristen Ganjoo, MD, Michael E. Williams, MD, Myron S. Czuczman, MD, K. Sue Robinson, MD, Robin Joyce, MD, Richard H. van der Jagt, MD, Bruce D. Cheson, MD

Blood (2007) 110 (11): 1351.

https://doi.org/10.1182/blood.V110.11.1351.1351

Published: 2007

Journal Articles

Durable Responses with Bortezomib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL): Updated Time-to-Event Analyses of the Multicenter PINNACLE Study.

Andre Goy, Steven Bernstein, Brad Kahl, Benjamin Djulbegovic, Michael Robertson, Sven de Vos, Elliot Epner, Amrita Krishnan, John Leonard, Sagar Lonial, Edward Stadtmauer, Owen O’Connor, Hongliang Shi, Anthony Boral, Richard Fisher

Blood (2007) 110 (11): 125.

https://doi.org/10.1182/blood.V110.11.125.125

Published: 2007

NARROW

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL

MYC Associated and Double Protein Lymphoma: Subset Analysis of SWOG S9704

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab

Identification of Potential Prognostic Biomarkers in Mantle Cell Lymphoma by Array-Based Quantitative Nuclease Protection Assay

Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies

A Randomized Phase III Trial of ABVD Vs. Stanford V +/− Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496)

A Phase 2, Double-Blind, Placebo-Controlled Trial of Rituximab + Galiximab Vs Rituximab + Placebo In Advanced Follicular Non-Hodgkin's Lymphoma (NHL)

R-CHOP Versus (vs) CHOP Followed by Maintenance Rituximab (MR) Vs Observation In Older Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Long-Term Follow-up of Intergroup E4494/C9793

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496

A Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell Lymphoma.

Predictors of Clinical Outcome to Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath for Relapsed/Refractory CLL – A Study of the Eastern Cooperative Oncology Group, E2903.

VcR-CVAD Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A Phase II Study from the Wisconsin Oncology Network

Phase II Study of R-CHOP Followed by 90 Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499.

Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma.

Durable Responses with Bortezomib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL): Updated Time-to-Event Analyses of the Multicenter PINNACLE Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only